Clinical Research Papers:
Metabolic syndrome contributes to an increased recurrence risk of non-metastatic colorectal cancer
Metrics: PDF 1544 views | HTML 1861 views | ?
Jie You1,*, Wen-Yue Liu2,*, Gui-Qi Zhu3,4, Ou-Chen Wang1, Rui-Min Ma1, Gui-Qian Huang3,5,*, Ke-Qing Shi3,6, Gui-Long Guo1, Martin Braddock7, Ming-Hua Zheng3,6
1Department of Oncological Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
2Department of Endocrinology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
3Department of Infection and Liver Diseases, Liver Research Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
4School of the First Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, China
5Renji School of Wenzhou Medical University, Wenzhou, China
6Institute of Hepatology, Wenzhou Medical University, Wenzhou, China
7Global Medicines Development, AstraZeneca R&D, Alderley Park, United Kingdom
*These authors have contributed equally to this work
Ming-Hua Zheng, e-mail: email@example.com
Ou-Chen Wang, e-mail: firstname.lastname@example.org
Keywords: non-metastatic colorectal cancer, metabolic syndrome, overall survival, disease-free survival, risk factor
Received: March 27, 2015 Accepted: June 01, 2015 Published: June 12, 2015
Objectives: Epidemiological data suggests a close link between metabolic syndrome (MetS) and non-metastatic colorectal cancer (NMCRC). However, the relationship between MetS and the outcome of NMCRC is less well understood. We aim to evaluate the impact of MetS on the prognosis in NMCRC patients.
Methods: We performed a large cohort study of 1069 NMCRC patients. The Kaplan-Meier method was used to calculate the cumulative survival rate. Cox proportional hazard regression models were used to analyze the prognosis associated with MetS adjusting for clinicopathologic variables.
Results: MetS was identified in 20.7% of NMCRC patients. Patients with MetS were more likely to be older, higher levels of blood glucose, triglycerides, high density lipoprotein, and uric acid than patients without MS (P < 0.05 for all). During a mean period of 59.6 months follow-up, patients with MetS had a statistically significantly lower rate of disease-free survival (DFS) than the patients without MetS (P = 0.014), especially local recurrence (P = 0.040). However, there was no difference in overall survival (P = 0.116). Multivariate analysis showed that the presence of MetS was an independent risk factor for DFS (HR = 0.733, 95%CI 0.545–0.987, P = 0.041), but not for OS (P = 0.118).
Conclusions: MetS is associated with an increased recurrence risk of NMCRC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.